Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

NCT03060980 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

245

Enrollment

INDUSTRY

Sponsor class

Stopped Decision by Sponsor

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: ITCA 650 20/60 mcg/day
DRUG: Empagliflozin (oral)
DRUG: Glimepiride (oral)

Sponsor

Intarcia Therapeutics